Results 181 to 190 of about 155,160 (352)
ABSTRACT There have only been a limited number of case reports that have described vulval lichen sclerosus in patients receiving immune checkpoint inhibitor (ICI) therapy. We describe 11 cases of vulval lichen sclerosus in patients with melanoma treated with ICIs, and in nine of these cases, the lichen sclerosus symptoms began after ICI commencement ...
Sophie Walter +9 more
wiley +1 more source
Pancreatic Cancer Risk in Hereditary Chronic Pancreatitis. [PDF]
Scherübl H.
europepmc +1 more source
Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors
Summary Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune‐related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence ...
Lisa Argnani +9 more
wiley +1 more source
Pancreatic tissue and ductal pressures in chronic pancreatitis [PDF]
N D Karanjia, A L Widdison, H A Reber
openalex +1 more source
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Clinical Spectrum and Management of Paediatric Chronic Pancreatitis. [PDF]
Zeeshan N +4 more
europepmc +1 more source
Effects of intraduodenally applied bile salts on pancreatic secretion [PDF]
Lehnert, Peter, Riepl, Rudolf L.
core +1 more source
Biliary Pancreatic Portal Fistula as a Complication of Chronic Pancreatitis
Ib Rasmussen +2 more
openalex +2 more sources
Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE‐522 Japan Subgroup Analysis
In the global, phase 3 KEYNOTE‐522 study of high‐risk early‐stage triple‐negative breast cancer (TNBC), neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improved efficacy outcomes versus neoadjuvant chemotherapy alone. In this analysis of Japanese participants from KEYNOTE‐522, neoadjuvant pembrolizumab plus chemotherapy ...
Masato Takahashi +16 more
wiley +1 more source
Shifts in amino acids profile in chronic pancreatitis. [PDF]
Malvik M +5 more
europepmc +1 more source

